Bioreductive activation and drug chaperoning in cobalt pharmaceuticals

Matthew D. Hall; Timothy W. Failes; Natsuho Yamamoto; Trevor W. Hambley

doi:10.1039/B707121C

skip RSC | ChemSpider | Feedback

Home > Journals > Dalton Transactions > Bioreductive activation...

Authors & Referees | Librarians

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

Dalton Transactions

Issue 36, 2007

More about this Journal
Editorial Board
Submit an Article

Follow Journal | |

Journal Home | RSC Journals

Perspective

Previous Article | Next Article

Bioreductive activation and drug chaperoning in cobalt pharmaceuticals

Matthew D. Hall , Timothy W. Failes , Natsuho Yamamoto and Trevor W. Hambley

Dalton Trans., 2007, 3983-3990

DOI: 10.1039/B707121C
Received 11 May 2007, Accepted 26 Jul 2007
First published on the web 08 Aug 2007

Please wait while Download options loads

Request Permissions

Abstract
Cited by
Related Content

The potential for cobalt(III) complexes in medicine, as chaperones of bioactive ligands, and to target tumours through bioreductive activation, has been examined over the past 20 years. Despite this, chemical properties such as reduction potential and carrier ligands required for optimal tumour targeting and drug delivery have not been optimised. Here we review the chemistry of cobalt(III) drug design, and recent developments in the understanding of the cellular fate of these drugs.

Terms & Conditions|Privacy |Accessibility|ACAP Enabled

Dalton Transactions

Bioreductive activation and drug chaperoning in cobalt pharmaceuticals

Log in (Free Access)

Log in (Subscriber Access)

Articles By